These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9373452)

  • 1. An analysis of testosterone implants for androgen replacement therapy.
    Handelsman DJ; Mackey MA; Howe C; Turner L; Conway AJ
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):311-6. PubMed ID: 9373452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone release rate and duration of action of testosterone pellet implants.
    Kelleher S; Howe C; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):420-8. PubMed ID: 15049955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrusion of testosterone pellets: a randomized controlled clinical study.
    Kelleher S; Turner L; Howe C; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 1999 Oct; 51(4):469-71. PubMed ID: 10583314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants.
    Kelleher S; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):531-6. PubMed ID: 11678837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate.
    Kelleher S; Conway AJ; Handelsman DJ
    Eur J Endocrinol; 2002 Apr; 146(4):513-8. PubMed ID: 11916619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis.
    Cavender RK; Fairall M
    J Sex Med; 2009 Nov; 6(11):3177-92. PubMed ID: 19796052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism.
    Zacharin MR; Pua J; Kanumakala S
    Clin Endocrinol (Oxf); 2003 Jun; 58(6):691-5. PubMed ID: 12780744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone Pellet Implantation Practices: A Sexual Medicine Society of North America (SMSNA) Member Questionnaire.
    Piecuch MJ; Patel BG; Hakim L; Wang R; Sadeghi-Nejad H
    J Sex Med; 2017 Jan; 14(1):47-49. PubMed ID: 27989489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of testosterone pellets in man.
    Handelsman DJ; Conway AJ; Boylan LM
    J Clin Endocrinol Metab; 1990 Jul; 71(1):216-22. PubMed ID: 2115044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.
    McMahon CG; Shusterman N; Cohen B
    J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with transdermal testosterone replacement therapy for hypogonadal men.
    Parker S; Armitage M
    Clin Endocrinol (Oxf); 1999 Jan; 50(1):57-62. PubMed ID: 10341856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism.
    Smith RP; Khanna A; Coward RM; Rajanahally S; Kovac JR; Gonzales MA; Lipshultz LI
    J Sex Med; 2013 Sep; 10(9):2326-33. PubMed ID: 23859250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes with the "V" implantation technique vs. standard technique for testosterone pellet therapy.
    Conners W; Flinn K; Morgentaler A
    J Sex Med; 2011 Dec; 8(12):3465-70. PubMed ID: 21883944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
    Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
    J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men.
    Fennell C; Sartorius G; Ly LP; Turner L; Liu PY; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2010 Jul; 73(1):102-9. PubMed ID: 19891698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low complication rates of testosterone and estradiol implants for androgen and estrogen replacement therapy in over 1 million procedures.
    Donovitz GS
    Ther Adv Endocrinol Metab; 2021; 12():20420188211015238. PubMed ID: 34104398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion.
    McCullough AR; Khera M; Goldstein I; Hellstrom WJ; Morgentaler A; Levine LA
    J Sex Med; 2012 Feb; 9(2):594-601. PubMed ID: 22240203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
    Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of androgen deficiency and replacement on prostate zonal volumes.
    Jin B; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.